Tag : Oncology & Rare Diseases

Healthcare Quality, Patient Safety & Policy

Revolution, Summit to Test RAS(ON) Drugs with Ivonescimab

Business Wire
by Business Wire082
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a...
Workforce Development & Leadership

STORM Therapeutics Names Dr. Eric Martin as Chief Development Officer

PR Newswire
by PR Newswire085
STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced the appointment of accomplished cancer biologist...
Clinical Research, Pharma & Healthcare Financing

Innovent Presents Phase 3 DREAMS-1 Study of Mazdutide at ADA 85th

PR Newswire
by PR Newswire0114
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and...
Clinical Research, Pharma & Healthcare Financing

Simcere Zaiming Doses First US Patient in SIM0500 Phase 1 Trial

PR Newswire
by PR Newswire087
Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1...
Clinical Research, Pharma & Healthcare Financing

TFS HealthScience expands collaboration with Oncomatryx for OMTX705 trial

PR Newswire
by PR Newswire0125
TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with Oncomatryx, a biopharmaceutical company developing novel antibody-drug conjugates (ADCs) targeting...